Owen Dunn is currently on a leave of absence from the firm on a secondment.

Owen Dunn helps clients navigate major matters that present complex legal and reputational risks. His practice concentrates on parallel criminal and civil investigations in matters involving the federal government across a spectrum of highly regulated industries, including life sciences and military procurement.

Mr. Dunn has experience working with companies to investigate alleged wrongdoing and to counsel clients on compliance, corrective actions, and all stages of litigation. He brings his experience and judgment to bear in providing practical advice for responding to immediate crises and handling matters at the intersection of government investigations, congressional oversight, and enforcement actions.

Mr. Dunn also litigates complex civil rights and constitutional law cases. Most recently, he represented former FBI Deputy Director Andrew McCabe in his wrongful termination lawsuit under the First and Fifth Amendments, including negotiations for the settlement restoring Mr. McCabe's retirement status and benefits.

Before joining the firm, Mr. Dunn served as a law clerk to the Honorable Eric L. Clay of the US Court of Appeals, Sixth Circuit. He also worked in the United States Senate, where he was a law clerk to the Permanent Subcommittee on Investigations, and in the US Department of Justice, where he was a law clerk to the Civil Division's Appellate Staff. He received his JD, magna cum laude, from the Georgetown University Law Center, and he was awarded the Order of the Coif upon graduation.


  • Former members of Congress as amici curiae supporting the investigation of the US House Select Committee to Investigate the January 6th Attack on the United States Capitol. Trump v. Thompson, et al., US District Court for the District of Columbia (1:21-cv-02769-TSC).
  • National diagnostic testing company in a multi-year investigation of the company's referral arrangements with physicians by the US Department of Justice, Office of the Inspector General for the US Department of Health & Human Services, and state office of the attorney general.
  • Boards of directors and C-Suite executives in designing corrective action plans and navigating high-stakes criminal and civil actions, including managing legal, financial, and reputational risks.
  • A major defense procurement company in an ongoing civil False Claims Act (FCA) qui tam suit brought on behalf of the federal government and alleging hundreds of millions of dollars in damages.
  • Life sciences companies in complex regulatory disputes with state and federal Medicare agencies, including active suspensions and threatened debarment and civil monetary penalties.
  • Bristol-Myers Squibb and Sanofi in two federal False Claims Act (FCA) qui tam suits and multiple state attorney general actions concerning the promotion of the pharmaceutical drug PLAVIX®.


FY 2022 FCA Year in Review
Qui Notes: Unlocking the False Claims Act
False Claims Act Update for Compliance and Payors
Health Ethics Trust, Best Practices Forum
Compliance Certification Intensive Course for Healthcare Compliance Professionals
Speaker, Crisis Averted: Preparing Your Healthcare Company to Handle a Government Subpoena
Washington Executive Certification Course for Healthcare Compliance Executives
Speaker, Health Ethics Trust Online Conference
Promoting FCA Cooperation Guidance, DOJ Dangles Discretion to Make FCA Allegations Go POOF!
Qui Notes: Unlocking the False Claims Act


  • J.D., Georgetown University Law Center, 2016, magna cum laude, Order of the Coif
  • Sc.B., Brown University, 2010
  • District of Columbia
  • U.S. Court of Appeals for the Sixth Circuit
  • U.S. District Court, Central District of Illinois
  • U.S. District Court, District of Columbia
  • U.S. Court of Appeals for the Sixth Circuit, The Honorable Eric L. Clay

Email Disclaimer